SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA and AIMT Shareholders About Its Ongoing Investigations

NEW YORK, Sept. 11, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

Akcea Therapeutics, Inc. (NASDAQ: AKCA)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akcea Therapeutics, Inc. (NASDAQ: AKCA) in connection with the proposed acquisition of the company by Ionis Pharmaceuticals, Inc. ("IONS").  Under the terms of the acquisition agreement, which is structured as a tender offer, AKCA shareholders will receive $18.15 in cash for each share of AKCA common stock that they own.   If you own AKCA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://weisslawllp.com/news/akcea-therapeutics-inc/  

Aimmune Therapeutics, Inc. (NASDAQ: AIMT)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aimmune Therapeutics, Inc. (NASDAQ: AIMT) in connection with the proposed acquisition of the company by Sociétés des Produits Nestlé S.A. ("Nestlé").  Under the terms of the acquisition agreement, which is structured as a tender offer, AIMT shareholders will receive $34.50 in cash for each share of AIMT common stock that they own.  If you own AIMT shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://weisslawllp.com/news/aimmune-therapeutics-inc/  

SOURCE WeissLaw LLP